Abstract
The effects of testosterone (TEST) treatment on markers of skeletal muscle ribosome biogenesis invitro and invivo were examined. C2 C12 myotubes were treated with 100nm TEST for short-term (24-h) and longer-term (96-h) treatments. Moreover, male 10-month-old Fischer 344 rats were housed for 4weeks, and the following groups were included in this study: (i) Sham-operated (Sham) rats, (ii) orchiectomised rats (ORX) and (iii) ORX+TEST-treated rats (7.0mgweek-1 ). For invitro data, TEST treatment increased c-Myc mRNA expression by 38% (P=0.004) after 96h, but did not affect total RNA, 47S pre-rRNA, Raptor mRNA, Nop56 mRNA, Bop1 mRNA, Ncl mRNA at 24h or 96h following the treatment. For invivo data, ORX decreased levator ani/bulbocavernosus (LABC) myofibril protein versus Sham (P=0.006), whereas ORX+TEST (P=0.015) rescued this atrophic effect. ORX also decreased muscle ribosome content (total RNA) compared to Sham (P=0.046), whereas ORX+TEST tended to rescue this effect (P=0.057). However, other markers of ribosome biogenesis including c-Myc mRNA, Nop56 mRNA, Bop1 mRNA, Ncl mRNA decreased with ORX independently of TEST treatments (P<0.05). Finally, lower phospho-(Ser235/236)-to-total rps6 protein and lower rpl5 protein levels existed in ORX+TEST rats versus other treatments, suggesting that chronic TEST treatment may lower translational capacity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
